RxDoctor Payments Data

Holly Elzey, NP

Family · Three Rivers, TXNPI 1649532029

Payments from drug & device makers

$2,228in general payments, 2019–2025

Across 109 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$753
  • Novo Nordisk$470
  • GSK$307
  • AstraZeneca$181
  • Exact Sciences$139
  • Amgen$64
  • plus $313 from 7 others

What the payments were for

  • Food & beverage$2,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,228 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$47,486
Medicare patients
221
Services billed
827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$132,823
MounjaroTirzepatide70$107,309
JardianceEmpagliflozin115$96,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$90,094
EliquisApixaban71$69,812
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$54,976
CreonLipase/Protease/Amylase16$48,452
FarxigaDapagliflozin Propanediol28$34,771
XareltoRivaroxaban24$22,983
MyrbetriqMirabegron18$19,181
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$13,244
Breo ElliptaFluticasone/Vilanterol18$11,568
SymbicortBudesonide/Formoterol Fumarate19$7,862
Albuterol Sulfate HfaAlbuterol Sulfate159$5,764
Ipratropium Bromide167$5,522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$470$132,823103 claims
Lilly USA, LLCMounjaro$753$107,30970 claims
GSKTrelegy Ellipta, Breo Ellipta$307$101,662113 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$181$97,608103 claims
PfizerEliquis, Paxlovid$52$73,85692 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Three Rivers

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →